- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Underscores the Potential of Mobile Health App in Healthcare Decisions
The study, conducted at the Columbia University School of Nursing, found that mobile apps with decision support features resulted in significantly higher diagnosis rates than apps with only bare-bones tools for recording results from a patient exam.
Smartphones and tablets may hold the key to getting more nurses to diagnose patients with chronic health issues like obesity, smoking, and depression—three of the leading causes of preventable death and disability. Mobile devices loaded with a custom app that prompts clinicians to follow evidence-based guidelines to make treatment decisions and document care plans makes nurses significantly more likely identify these health issues during routine exams, according to a study from Columbia University School of Nursing published in the Journal for Nurse Practitioners.
"What clinicians need is decision support tools that fit into their workflow and remind them of evidence-based practices," says lead study author Suzanne Bakken, PhD, RN, FAAN, FACMI, Alumni Professor of Nursing and Professor of Biomedical Informatics at Columbia Nursing. "Our app focused specifically on the work that nurse practitioners do to identify health problems, counsel patients, and coordinate care plans, resulting in higher diagnosis rates and more opportunities for intervention."
Read the complete report at MedicalXpress: http://bit.ly/1MEDe9e
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
